Phase 1 Mesothelioma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be willing and able to sign a written consent form agreeing to take part in the trial.
• You must be at least 18 years old on the day you sign the consent form.
• Your cancer must be measurable using standard imaging guidelines (confirm with trial site).
• You must be willing to provide a fresh tumor tissue sample (biopsy) taken within 6 weeks before starting treatment; in some cases, a previously stored sample may be accepted with approval from the trial organisers.
• You must be generally well enough to carry out daily activities, based on a standard health scale scoring 0 or 1 (confirm with trial site).
• Your kidneys, liver, and other organs must be working well enough, as shown by blood tests taken within 10 days of starting treatment.
• If you are a woman who could become pregnant, you must have a negative pregnancy test within 72 hours before your first dose.
• If you are a woman who could become pregnant, you must agree to use a reliable form of contraception during the study and for 120 days after your last dose (abstinence is acceptable if that is your normal practice).
• If you are a man who could father a child, you must agree to use a reliable form of contraception from your first dose until 120 days after your last dose (abstinence is acceptable if that is your normal practice).

Who may not be able to join:

• You are currently taking part in another clinical trial or have received an experimental treatment or used an experimental device within the last 4 weeks.
• You have been diagnosed with a weakened immune system, or you have taken immune-suppressing medicines or high-dose steroid tablets (above a certain daily amount) within the last 7 days — though people who occasionally use inhalers or local steroid injections for asthma or lung conditions would not be excluded.
• You have a known history of active tuberculosis (TB).
• You have a known allergy or sensitivity to either of the study drugs (ICG or pembrolizumab) or any of their ingredients.
• You have received a type of cancer treatment called a monoclonal antibody within the last 4 weeks, or you are still experiencing significant side effects from a previous monoclonal antibody treatment.
• You have had chemotherapy, targeted cancer medicines, or radiotherapy within the last 2 weeks, or you are still experiencing significant side effects from previous cancer treatment; if you have had major surgery, you must have fully recovered before starting.
• You have another cancer that is growing or currently being treated, except for certain skin cancers or early-stage cervical cancer that have been successfully treated.
• Your cancer has spread to other parts of the body or has been determined to be inoperable (cannot be removed by surgery).
• You have an autoimmune disease (where the immune system attacks the body) that has needed medical treatment in the past 2 years — though simple hormone or replacement therapies do not count as this type of treatment.
• You have a history of lung inflammation (not caused by infection) that needed steroid treatment, or you currently have lung inflammation.
• You have evidence of a scarring or inflammatory lung condition (confirm with trial site).
• You currently have an active infection that requires medicine taken throughout your body (such as antibiotics or antivirals).
• You have any other condition, health history, or abnormal test result that the trial doctor believes could affect your safety or the trial results.
• You have a known mental health condition or substance use problem that might make it difficult to follow the trial requirements.
• You are pregnant, breastfeeding, or planning to become pregnant or father a child during the trial period or within 120 days after the last dose.
• You have previously been treated with a specific type of immunotherapy drug called an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (confirm with trial site).
• You have a known history of HIV.
• You have known active Hepatitis B or Hepatitis C infection.
• You have received a live vaccine within 30 days before starting the trial — most standard flu injections are allowed, but nasal spray flu vaccines are not.

Important: Always verify eligibility with the trial site directly before applying.